SBIR awards for seed funding islet research

Company	Award Title	Phase	Award Year	Award Amount
21st Century Medicine, Inc.	Automated High Throughput Cryopreservation Using Microfluidics	Phase I	2010	251046
ADAPTIVE BIOTECHNOLOGIES CORPORATION	Development of T-cell receptor repertoire profiling as a diagnostic for T1D	Phase I	2010	632685
ADVANCED BIOLOGICAL TECHNOLOGIES	A Novel Method to Isolate Islet Cells	Phase I	2007	181195
Allergy Immuno Technologies	ELISAS FOR ISLET CELL AUTOIMMUNITY AND PREDIABETES	Phase I	1988	46000
APOIMMUNE, INC	ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates	Phase I	2010	803836
APOIMMUNE, INC	ApoFasL: a Novel Immunotherapeutic for T1D	Phase I	2007	421676
APT THERAPEUTICS, INC.	Magnetic Flow Sorter for Pancreatic Islet Isolation	Phase I	2013	288298
ARTIUM TECHNOLOGIES INC	OPTICAL DIAGNOSTICS FOR THE ANALYSIS AND SELECTION OF ENCAPSULATED ISLETS	Phase I	2002	0
ARTIUM TECHNOLOGIES INC	OPTICAL DIAGNOSTICS FOR THE ANALYSIS AND SELECTION OF ENCAPSULATED ISLETS	Phase II	2002	749996
ARTIUM TECHNOLOGIES INC	Encapsulation of Islets for the Treatment of Diabetes	Phase I	2001	94325
AVID RADIOPHARMACEUTICALS, INC.	18F-FP-DTBZ for PET Imaging of Beta Cell Mass in Diabetes	Phase I	2007	247050
BETASTEM THERAPUETICS, INC.	Progenitor assay to screen proteins/molecules for treatment of type1 diabetes	Phase I	2007	198752
BioHybrid Technologies Inc.	Islet Transplantation Using Implantable Microreactors	Phase II	1995	749997
BioHybrid Technologies Inc.	Islet Transplantation Using Implantable Microreactors	Phase I	1994	80999
BIOINVENTIONS, LLC	Islet Protection from Hypoxia Posttransplant	Phase I	2010	332135
BIOREP TECHNOLOGIES, INC.	A perfluorocarbon-based culture device for beta cell biology applications	Phase I	2009	100000
Cell & Tissue Systems, Inc.	Commercial Feasibility Assessment of Pancreatic Islet Progenitor Cell Technology	Phase I	2007	151958
Cell & Tissue Systems, Inc.	New Solutions Islet Recovery Preservation of Pancreas	Phase II	2007	593914
Cell & Tissue Systems, Inc.	New Solutions Islet Recovery Preservation of Pancreas	Phase I	2006	161977
Cell & Tissue Systems, Inc.	Pancreas Transporter Development and Validation	Phase II	2005	1005430
CELL PRESERVATION SERVICES, INC.	Improving Pancreas/Islets Preservation HTS/CryoStor	Phase I	2006	552665
Cell-Safe Life Sciences LLC	An Ultra filtrate perfusion bio artificial pancreas for high density islet replacement without immunosuppression	Phase II	2017	779153
Cellular Transplantation	CRYOPRESERVATION OF PANCREATIC ISLET CELLS	Phase I	1988	50000
CG SCIENTIFIC, INC.	Automated System for High Yield Pancreatic Islet Isolation	Phase I	2017	299996
Chrysallis Research Laboratori	FAST LIGAND FOR PROTECTION OF TRANSPLANTED B ISLET CELLS	Phase I	1998	99862
CIENCIA INC	MHC Array T Cell Assay System for Monitoring Immune Status in Type 1 Diabetes	Phase I	2007	504097
CORIXA CORPORATION	VACCINE: AUTO-IMMUNE DESTRUCTION OF TRANSPLANTED ISLETS	Phase I	1999	79007
Crinetics Pharmaceuticals, Inc.	Nonpeptide oral somatostatin agonists for congenital hyperinsulinemias	Phase I	2017	297358
Cyborgan, Inc.	Ommaya Artificial Organ for Islet Transplantation	Phase I	1994	73451
CYTOMETRY RESEARCH, LLC	ISOLATION OF PANCREATIC ISLETS BY FACS	Phase I	2002	100000
Cytotherapeutics, Inc.	OPTIMAL ISLET MATRIX FOR IMMUNOISOLATED TRANSPLANTS	Phase I	1991	50000
Diacrin, Inc.	Xenotransplantation of Pancreatic Islets	Phase I	1994	58585
EDWARD POPE DR	CERAMIC GEL ENCAPSULATION ISLETS FOR TREATING DIABETES	Phase I	1996	94300
ELECTROSONICS MEDICAL INC	Novel Acoustic Method: Rapid, High-Yield Islet Isolation	Phase I	2001	133321
ELGAVISH PARAMAGNETICS, INC.	MRI Quantification of Postinfarct Myocardial Viability	Phase II	2007	380811
ELGAVISH PARAMAGNETICS, INC.	MRI Quantification of Postinfarct Myocardial Viability	Phase I	2005	100000
Enable Biosciences	Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring	Phase I	2016	224423
Enteratech, Inc.	Combined Effects for Improved Tissue Dissociation	Phase I	2005	367647
Enteratech, Inc.	Video Assisted Islet Cell Isolation System	Phase I	2004	499568
EPIVAX, INC.	T1D Tolerance Induction with Natural Treg Epitopes	Phase I	2008	599999
Fairbanks Pharmaceuticals Inc	Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity	Phase I	2016	192101
FasCure Therapeutics LLC	SA FasL engineered human islets as a novel product for the treatment of type diabetes	Phase I	2017	224529
GENERAL BIOTECHNOLOGY, LLC	EXPANSION OF PANCREATIC ISLETS USING A NOVEL BIOMATERIAL	Phase I	2001	0
GENERAL BIOTECHNOLOGY, LLC	EXPANSION OF PANCREATIC ISLETS USING A NOVEL BIOMATERIAL	Phase II	2001	388521
GENERAL BIOTECHNOLOGY, LLC	EXPANSION OF PANCREATIC ISLETS USING NOVEL BIOMATERIAL	Phase I	1999	99997
Giner, Inc.	Pressure Management Technologies for Oxygenation of Implanted Insulin Secreting Cells	Phase I	2017	224936
Giner, Inc.	High Cell Density Bioartificial Pancreas Enabled by Implantable Oxygen Generator	Phase II	2015	1954584
Giner, Inc.	Portable Gas Perfusion System for Pancreas Preservation	Phase II	2014	1990947
Giner, Inc.	Portable Gas Perfusion System for Pancreas Preservation	Phase II	2010	1610840
Giner, Inc.	Low-Cost Carbon Dioxide Generator for Cylinder-Free Cell Culture Incubators	Phase I	2008	146749
Giner, Inc.	Cylinder-Free Atmosphere Control for Incubators	Phase II	2006	785136
Giner, Inc.	Oxygen Gas Perfusion System for Pancreas Preservation	Phase I	2006	499997
Giner, Inc.	PORTABLE ISLET CULTURE SYS	Phase I	2004	0
Giner, Inc.	PORTABLE ISLET CULTURE SYS	Phase II	2004	405765
HOUSEY PHARMACEUTICAL RESEARCH LAB	Discovery and Development of Antidiabetic Drugs	Phase II	2006	852467
IMEDD, INC.	IMMUNOISOLATION BIOCAPSULES FOR PANCREATIC ISLET CELLS	Phase I	2002	0
IMEDD, INC.	IMMUNOISOLATION BIOCAPSULES FOR PANCREATIC ISLET CELLS	Phase II	2002	758904
Immco Diagnostics Inc.	STANDARDIZATION OF ASSAY FOR ANTIBODIES TO ISLET CELLS	Phase II	1988	350000
Immco Diagnostics Inc.	STANDARDIZATION OF ASSAY FOR ANTIBODIES TO ISLET CELLS	Phase I	1986	49000
Inotek Pharmaceuticals Corporation	PARS INHIBITOR FOR ISLET CELL TRANSPLANT REJECTION	Phase I	1999	99998
ISOGENIS, INC.	Veto-ing the Rejection of Allogeneic HSCs	Phase I	2007	300001
ISOGENIS, INC.	Protecting Pancreatic Islet Grafts from Rejection	Phase II	2006	2996220
ISOGENIS, INC.	Protecting Pancreatic Islet Grafts from Rejection	Phase I	2004	866830
IXION BIOTECHNOLOGY, INC.	Conversion of long-term cultured human pancreatic cells into functional islets	Phase I	2006	188420
IXION BIOTECHNOLOGY, INC.	DIABETES THERAPY--FACTORS CONTROLLING ISLETs	Phase I	1996	93459
L2 DIAGNOSTICS, LLC	Therapeutic Inhibition of MIF in Type 1 Diabetes	Phase I	2015	297302
L2 DIAGNOSTICS, LLC	Measurement of Beta Cell Death in Diabetes	Phase II	2014	1348103
LI-COR, Inc.	Next Generation Western for high-throughput and high-content protein analysis	Phase I	2014	520603
Medical Diagnostic Tech Inc	THIS PROJECT WILL DEVELOP A TEST WITH PROSPECTIVE COMMERCIALAPPLICATION TO IDENTIFY PANCREATIC ISLET CELL ANTIBODIES (ICA) WHOSE PRESENCE IN HUMAN SERUM IS INDICATIVE OF PRE- INSULIN-DEPENDENT DIABETES MELLITIS (IDDM) OR ITS VERY EARLYSTAGES.	Phase I	1986	50000
METAFOLD THERAPEUTICS, INC.	Cytoprotective Effects of UPR Modulators in ER Stress-Challenged beta-Cells	Phase I	2009	152520
MICROISLET, INC.	Improving Porcine Islet Function and In Vivo Survival with Lisofylline	Phase I	2008	242166
MICROISLET, INC.	Encapsulated Porcine Islets into Rhesus Macaques	Phase II	2005	1708480
MICROISLET, INC.	Optimization & Automation of Pancreatic Islet Isolation	Phase I	2003	119630
MIRNATECH INTERNATIONAL INC	MiRNAs as serum biomarkers for T1D	Phase I	2016	267900
Montana Molecular LLC	A robust assay for detecting agonist bias in living cells	Phase I	2017	193000
MULTICELL TECHNOLOGIES, INC.	Engineered human lgG1 for delivery of IDDM self-epitopes	Phase I	2006	210000
NESHER TECHNOLOGIES, INC.	Autoantibody- and microRNA-based Next-Gen Multiplex Test for Type 1 Diabetes	Phase I	2015	150000
NEUROX PHARMACEUTICALS, LLC	Novel SOD-mimetics for type 1 diabetes	Phase I	2006	207730
NIRMIDAS BIOTECH, INC.	Development of multiplexed autoantibody test on pGOLD platform for Diagnosis and Screening of Type Diabetes	Phase II	2017	496692
Norfolk Medical Products, INC.	An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression	Phase I	2016	223278
NOVEOME BIOTHERAPEUTICS, INC.	Differentiation of Amnion-Derived Cells to Islet Cell Types	Phase I	2006	147700
NOVOMEDIX, LLC	Discovery and Development of Compounds to Enhance b-cell Number and Function	Phase I	2007	516697
ONE CELL SYSTEMS, INC	Microdrop Culture and Analysis of Fetal Islets	Phase I	1995	100000
Ophysio Inc.	Preclinical characterization of THR to induce pancreatic beta cell regeneration Phase I	Phase I	2017	223876
Ophysio Inc.	technologyIn vitro maturation of BMP responsive pancraeatic beta cell progenitors by oxygen modulation	Phase II	2016	1443038
Ophysio Inc.	In vitro maturation of BMP-7-responsive pancreatic beta cell progenitors by oxygen modulation technology	Phase I	2015	224985
OPTIKIRA, LLC	IRE1 alpha inhibitors for type 2 diabetes	Phase I	2015	199611
Op-T-Mune, Inc	Developing a small peptide to control autoimmune inflammation in type diabetes	Phase I	2017	297387
ORGAN RECOVERY SYSTEMS, INC.	VITRIFICATION OF GENETICALLY-ENGINEERED ISLETS	Phase I	2001	111280
PANORAMA RESEARCH	Novel NMDA Receptor Antagonists for Beta Cell Rescue	Phase I	2015	224620
Pharmain Corporation	EGF/Gastrin for Islet Regeneration	Phase II	2013	1543646
Pharmain Corporation	EGF/Gastrin for islet cell regeneration	Phase I	2009	443608
Pharmain Corporation	Long Acting Native GLP-1 formulations for Type 1 Diabetes	Phase II	2007	914882
PLUREON CORP.	Cell therapy of diabetes using broad spectrum multipotent stem cells	Phase I	2006	999977
PRIMORIGEN BIOSCIENCES INC.	A Novel Multiplexed Assay for Rapid Antibody Screening	Phase II	2010	1569690
PRODO LABORATORIES, INC.	NOVEL THERMAL REVERSIBLE POLYMER (TRG) FOR HUMAN ISLET ENCAPSULATION AND IMPLANTA	Phase I	2011	226975
PRODYNE CORPORATION	Ultrasonic Measurement of Islet Volume	Phase I	2003	496530
PROFUSA, INC.	Wireless Technology for Long Term Non Invasive O Sensing within Cell Encapsulation Devices in Vivo	Phase I	2017	224911
Progenra, Inc	Targeting SUMO proteases for type II diabetes	Phase I	2010	271286
Propagenix Inc	Enhancement of Conditional Reprogramming Technology for Production of Functional Human Beta Cells	Phase I	2017	225000
PULSAR CLINICAL TECHNOLOGIES, INC.	Multiplex Microarray for the Detection of Pre-Type 1 Diabetes Autoantibodies	Phase II	2008	840406
PULSAR CLINICAL TECHNOLOGIES, INC.	Multiplex Microarray for the Detection of Pre-Type 1 Diabetes Autoantibodies	Phase I	2007	103413
REGENERATIVE MEDICAL SOLUTIONS INC	Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function	Phase I	2016	224964
REGENERATIVE MEDICAL SOLUTIONS INC	Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem cells	Phase I	2016	224930
REGENERATIVE MEDICAL SOLUTIONS INC	Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing	Phase II	2015	1499949
RESODYN CORPORATION	Mechanical Induced Resonant Mixing for Islet Separation	Phase I	2004	129608
RIBONOMICS, INC.	RNA Binding Proteins and Beta-cell Function	Phase I	2004	463050
RST IMPLANTED CELL TECHNOLOGY, INC.	Interaction between islets and implantable immunoisolation polyurethane membranes	Phase I	2006	100000
Sepragen Corporation	STTR Phase I: Novel Wicking Matrix Bioreactor for Pluripotent and Progenitor Cell Expansion	Phase I	2017	224999
SERTOLI CELL RES INST	XENOGRAFTING OF PORCINE ISLET/SERTOLI CELL COMPOSITES	Phase I	1999	81351
SERTOLI CELL RES INST	ISLET GRAFTS IN SERTOLI CELL IMMUNOPRIVILEGED SITES	Phase I	1997	99523
STEMCELLLIFE LLC	Mass production of functional beta islet-like clusters	Phase I	2016	223899
SURMODICS, INC.	PHOTOINITIATED CONFORMAL ISLET ENCAPSULATION MATRICES	Phase I	1998	99774
SURMODICS, INC.	Photocrosslinkable Polymers for Islet Encapsulation	Phase I	1995	99947
Sylvatica Biotech, Inc.	Nature inspired methods for long term banking of endocrine cells within encapsulation devices	Phase I	2017	224347
Synthecon, Inc.	Methods for Improving Pancreatic Islet Transplantation	Phase II	2008	737846
Synthecon, Inc.	Methods for Improving Pancreatic Islet Transplantation	Phase I	2004	100170
Synthecon, Inc.	Methods for Improving Pancreatic Islet Transplantation	Phase I	2004	100170
TauTheta Instruments LLC	SBIR Phase I: Vertical Perfusion System for Cell Culture and Monitoring	Phase I	2006	100000
TECHSHOT, INC.	Magnetic Flow Sorter for Pancreatic Islet Isolation	Phase II	2013	2671250
TECHSHOT, INC.	Magnetic Flow Sorter for Pancreatic Islet Isolation	Phase II	2013	2671250
TECHSHOT, INC.	Magnetic Flow Sorter for Pancreatic Islet Isolation	Phase II	2008	1073840
TECHSHOT, INC.	Magnetic Flow Sorter for Pancreatic Islet Isolation	Phase I	2005	99650
TELIOS PHARMACEUTICALS, INC.	SYNTHETIC RGD MATRIX TO SUPPORT ISLET TRANSPLANTATION	Phase I	1999	133798
ViaCyte, Inc.	Treatment of type diabetes with human embryonic stem cell derived pancreatic beta like cells	Phase II	2017	500370
VIRTICI LLC	A Novel Tolerance Therapeutic for Treating Type Diabetes	Phase I	2017	300000
VITACYTE, LLC	Digital image analysis for quantitative and qualitative assessment of pig islets	Phase I	2011	232329
VITACYTE, LLC	Tissue Dissociation Enzymes for Islets and Other Cells	Phase II	2009	1715220
VITACYTE, LLC	Improved recombinant collagenase for tissue dissociation	Phase I	2007	276028
VITACYTE, LLC	System to analyze factors affecting human islet yield	Phase I	2006	195331
VITACYTE, LLC	Tissue Dissociation Enzymes for Islets & Other Cells	Phase I	2004	572658
VITALQUAN LIMITED LIABILITY COMPANY	Zinc II Sensitive MRI Contrast Agents as Diagnostic Sensors for Tracking Insulin Secretion	Phase I	2017	180850
VITALQUAN LIMITED LIABILITY COMPANY	Fluorescent Probes for Tracking Insulin Secretion in Therapeutic and Diagnostic Devices	Phase II	2016	1400494
VITALQUAN LIMITED LIABILITY COMPANY	Fluorescent Probes for Tracking Insulin Secretion in Therapeutic and Diagnostic Devices	Phase I	2015	224628
Vivorx Pharmaceuticals, Inc.	Rechargeable Cell Containment Device--Pancreatic Islet	Phase I	1995	95582
Vivorx Pharmaceuticals, Inc.	Islets Encapsulated in Photopolymerizable Alginate	Phase I	1995	96500
Vivorx Pharmaceuticals, Inc.	Encapsulated Porcine Islets as a Bioartificial Pancreas	Phase I	1994	75000
WILSON WOLF MANUFACTURING CORPORATION	Islet culture, shipping, and infusion device	Phase II	2008	3764960
WILSON WOLF MANUFACTURING CORPORATION	Islet culture, shipping, and infusion device	Phase I	2004	933353
XIMEREX, INC.	PERV Free Swine for Xenotransplantation	Phase I	2008	600000
XIMEREX, INC.	Ex Vivo Induction of Tolerance for Autoimmune Diabetes	Phase I	2008	1267090
XIMEREX, INC.	Heart Xenotransplantation with Chimeric Donor Pigs	Phase I	2005	1086680
XIMEREX, INC.	Islet Transplantation with Chimeric Donor Pigs	Phase II	2004	3000000
ZEN-BIO, INC.	Development of a drug discovery platform for human islets	Phase II	2014	1754814
ZEN-BIO, INC.	Development of a Drug Discovery Platform for Human Islets	Phase I	2012	462386